Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first-line therapy for triple-negative, metastatic, or locally advanced breast cancer: Results from the GINECO A-TaXel phase 2 study.

Jean-Marc Ferrero,Anne-Claire Hardy-Bessard, Olivier Capitain,Alain Lortholary, Bruno Salles,Philippe Follana,Robert Herve,Mathilde Deblock,Jérôme Dauba, Mustapha Atlassi,Rémy Largillier

Cancer（2016）

引用 25|浏览17

暂无评分

摘要

A triplet regimen of paclitaxel, capecitabine, and bevacizumab followed by maintenance therapy with capecitabine and bevacizumab demonstrated high activity and manageable safety in this difficult-to-treat population. Cancer 2016;122:3119-26. © 2016 American Cancer Society.

查看译文

关键词

bevacizumab,capecitabine,combination chemotherapy,maintenance therapy,metastatic breast cancer,triple negative

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要